J&J Submits McNeil Plant Reforms To FDA, Announces Layoffs
This article was originally published in The Tan Sheet
Executive Summary
The firm submits a remediation plan for correcting quality control issues and investing in long-term improvements at its Fort Washington, Pa., plant. While the facility remains shuttered, about 75% of its positions are being eliminated and OTC production shifted elsewhere.
You may also be interested in...
J&J Must Lay Out Remediation Specifics To Regain Trust In OTCs – Expert
McNeil Consumer Healthcare continues on the long road back to full manufacturing strength and consumer confidence in its OTCs with an ongoing review of issues that have plagued the company with recalls.
Novartis Extends Triaminic Into Brand Name Void Left By J&J Tylenol Recall
Novartis expedites a Triaminic line extension to take advantage of the branded product gap left by the recall of Johnson & Johnson's Children's Tylenol liquid OTCs
Congress Hopes To Land J&J Chief Weldon For Second Recall Inquiry
House members again try to put Johnson & Johnson CEO William Weldon in the hot seat, asking him for the second time since May to testify on OTC quality control issues at J&J's McNeil Consumer Healthcare